Case Study: eCOA Science and Consulting Company achieves higher data quality and lower participant burden with Clario

Scientific experts at Clario helped a sponsor address concerns about the way its initial eCOA solution handled the collection of Adverse Event information

eCOA Science and Consulting Company engaged Clario’s Science Advisory team to rescue an early eCOA implementation that was creating participant confusion and poor data around “Adverse Events.” The initial solution used unclear wording, free-text fields, poor question sequencing and lack of branching, which increased respondent burden, risked incomplete or low-quality data and raised concerns about inadvertent medical device classification.

Clario redesigned the instrument—reducing a 46‑question diary to 16 essential questions, aligning the question order to the drug‑administration flow, removing unnecessary free text, adding branching and clarifying terminology—thereby averting regulatory risk. As a result, Clario delivered an eCOA instrument that produced more reliable, higher‑quality data with higher compliance and lower participant burden.